Short-term effects of Lumacaftor/Ivacaftor (Orkambi™) on exertional symptoms, exercise performance, and ventilatory responses in adults with cystic fibrosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-993X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Short-term effects of Lumacaftor/Ivacaftor (Orkambi™) on exertional symptoms, exercise performance, and ventilatory responses in adults with cystic fibrosis ; volume:21 ; number:1 ; day:1 ; month:6 ; year:2020 ; pages:1-4 ; date:12.2020
Respiratory research ; 21, Heft 1 (1.6.2020), 1-4, 12.2020
- Urheber
-
Quon, Bradley S.
Ramsook, Andrew H.
Dhillon, Satvir S.
Mitchell, Reid A.
Boyle, Kyle G.
Wilcox, Pearce G.
Guenette, Jordan A.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12931-020-01406-z
- URN
-
urn:nbn:de:101:1-2020080401373209912880
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Quon, Bradley S.
- Ramsook, Andrew H.
- Dhillon, Satvir S.
- Mitchell, Reid A.
- Boyle, Kyle G.
- Wilcox, Pearce G.
- Guenette, Jordan A.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion
Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy
Ventilatory abnormalities in patients with cystic fibrosis undergoing the submaximal treadmill exercise test
Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction
Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience
Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor–Tezacaftor–Ivacaftor therapy
Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
Cystic fibrosis
Improved Nutritional Outcomes and Gastrointestinal Symptoms in Adult Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor
Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization
Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis
Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion
Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy
Ventilatory abnormalities in patients with cystic fibrosis undergoing the submaximal treadmill exercise test
Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction
Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience
Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor–Tezacaftor–Ivacaftor therapy
Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
Cystic fibrosis
Improved Nutritional Outcomes and Gastrointestinal Symptoms in Adult Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor
Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization
Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis
Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations
Lumacaftor/ivacaftor in cystic fibrosis: effects on glucose metabolism and insulin secretion
Predicting lung function decline in cystic fibrosis: the impact of initiating ivacaftor therapy
Ventilatory abnormalities in patients with cystic fibrosis undergoing the submaximal treadmill exercise test
Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction
Real-World Outcomes Among Patients with Cystic Fibrosis Treated with Ivacaftor: 2012–2016 Experience
Longitudinal microbial and molecular dynamics in the cystic fibrosis lung after Elexacaftor–Tezacaftor–Ivacaftor therapy
Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
Cystic fibrosis
Improved Nutritional Outcomes and Gastrointestinal Symptoms in Adult Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor
Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization